Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour I'Etude des Cancers Ovariens

2007 ◽  
Vol 2007 ◽  
pp. 69-70
Author(s):  
J.T. Thigpen
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Cancer ◽  
Advanced Ovarian Cancer ◽  
Study Group ◽  
Line Treatment ◽  
First Line ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Intergroup Trial ◽  
First Line Treatment

Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer

2007 ◽  
Vol 17 (2) ◽  
pp. 350-358 ◽  
Author(s):  
M. Friedlander ◽  
M. Buck ◽  
D. Wyld ◽  
M. Findlay ◽  
B. Fitzharris ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Gynecologic Cancer ◽  
Advanced Ovarian Cancer ◽  
Ca 125 ◽  
Line Treatment ◽  
First Line ◽  
Sequential Approach ◽  
First Line Treatment

The aim of this exploratory phase II study was to evaluate sequential chemotherapy with carboplatin followed by gemcitabine–paclitaxel combination in chemonaive patients with advanced ovarian cancer. The primary objective was to evaluate time to progressive disease (TTPD); secondary objectives included the evaluation of 1- and 3-year survival, response rates, and toxicity. Following initial debulking surgery or biopsy, patients with FIGO stage IIC–IV disease received four cycles of carboplatin area under the curve (AUC) 6 (day 1) every 21 days, followed by four cycles of gemcitabine 1000 mg/m2 (days 1 and 8) and paclitaxel 175 mg/m2 (day 8) every 21 days. A total of 47 patients enrolled, 44 (93.6%) completed the initial four cycles, and 39 patients (82.9%) completed the planned eight cycles. The median and maximum lengths of follow-up were 31.2 and 43.7 months, respectively. Median TTPD was 13.8 months (95% CI, 11.6–21.0 months), and median survival time was 31.2 months (95% CI, 25.2–39.6 months). Survival at 1 and 3 years was 95.7% and 44.2%, respectively. Of the 43 evaluable patients, most (95.3%) of them achieved a CA-125 marker response based on Gynecologic Cancer Intergroup (GCIG) definition. The partial response rate in the seven patients with measurable disease was 46.4%. Myelosuppression was the major toxicity, with grade 3 and 4 neutropenia observed in 76.6% patients and thrombocytopenia in 12.8% patients. The sequential approach of carboplatin followed by gemcitabine–paclitaxel as first-line treatment for patients with ovarian cancer is feasible and well tolerated, and depending upon the findings from other major trials, it may merit further evaluation.

Improving first-line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective

2003 ◽  
Vol 13 (Suppl 2) ◽  
pp. 169-171
Author(s):  
A. Du Bois ◽  
J. Pfisterer ◽  
W. Meier ◽  
U. Wagner
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Phase Iii ◽  
Ca 125 ◽  
Study Group ◽  
First Line ◽  
Cancer Study ◽  
First Line Therapy ◽  
Line Therapy ◽  
Cancer Study Group

This review displays the AGO Ovarian Cancer Study Group approach towards evaluation of improvement options in first-line therapy of advanced ovarian cancer. Prospectively randomized phase III trials evaluating the addition of newer drugs to standards carboplatin-paclitaxol (TC) as well as pilot trials evaluating new treatment modalities like anti-idiotype CA 125 antibodies or epidermal growth factor receptor (EGFR) modulation are presented.

Sign in / Sign up

Export Citation Format

Share Document